Posts tagged as: best biotechnology stocks back to homepage
 |
Dosing Underway with Cellceutix’s New Cancer Drug at Dana-Farber(0) Cellceutix Hits Major Milestone in Company History; Dosing Underway for New Cancer Drug at Leading Hospitals Kevetrin is First-in-Class of Novel Chemistry to Reach Clinical Stage Cellceutix Corporation (OTCBB: CTIX) (the “Company”), a clinical stage biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, is pleased to report that dosing of patients is now being conducted in clinical trials with Kevetrin(TM), the Company’s novel anti-cancer drug candidate, at Harvard University’s Dana Farber Cancer Center and Beth Israel Deaconess Medical Center. Read More |
 |
Five Regenerative Medicine Companies Worthy of Portfolio Addition(0) Broadly speaking, regenerative medicine is an innovative new area of medicine that is focused on the development of new therapies that enable healing and repair of the body in ways that overcome the limitations of conventional medical treatments. Regenerative medicine uses a range of approaches, including cell based therapies, stem cells, tissue engineering and others, that represent Read More |
 |
New Award and Recent Research Reaffirms Athersys as Leader in Regeneration Medicine(0) On the heels of a steady stream of corporate developments in October that showcased the promising data that continues to build regarding its MultiStem® cell therapy, Athersys, Inc. (NASDAQ: ATHX) announced Thursday morning that its subsidiary, ReGenesys BVBA, recently received the BioProcess International Award for the “Technical Application of the Decade” in Manufacturing for its use of an automated bioreactor system for the production of MultiStem. Read More |
 |
Excellagen Presentation on Cardium Therapeutics Website(0) An updated presentation for Excellagen has been published on the Cardium Therapeutics (NYSE MKT: CXM) website. The pdf file is available for viewing/dowloading at http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-presentations. Read More |
 |
Cardium to Present at Rodman and Renshaw Conference(0) Cardium to Present at the Rodman & Renshaw Annual 2012 Healthcare Investment Conference Cardium Therapeutics (NYSE MKT: CXM) today announced that Christopher J. Reinhard, Chairman & CEO will present at the Rodman & Renshaw Annual Healthcare Investment Conference on Monday, September 10, 2012 at 3:15 p.m. Eastern Time. The conference is being held September 9-11, 2012 at the Waldorf-Astoria Hotel in New York City. An audio webcast of the Company’s presentation will be available live and by replay and can be accessed at Read More |
 |
Cellceutix on Seeking Alpha: Pfizer Eyes Kevetrin?(0) An article from August 13 by Seeking Alpha contributor A. Jackson discussed the state of big pharma’s pipelines and the potential of Cellceutix (OTCBB: CTIX) anti-cancer drug, Kevetrin, as it enters clinical trials at Dana-Farber and Beth Israel Deaconess. More acutely, Jackson details the relationship between Pfizer and Cellceutix and why the smaller biotech could be a logical acquisition target for the world’s biggest drug maker. Read More |
 |
Cardium Therapeutics Excellagen Named as Top Ten Innovation in Podiatry(0) Last year, industry specialist GlobalData released a report estimating the global diabetic foot ulcer therapeutics market to be valued at $1.15 billion in 2010 with expectations of growth to $2.28 billion by 2017. A recent article by BBC News called today’s diabetic foot care “appalling” and leading to “an increased risk of having a foot amputated.” With their Excellagen product, Cardium Therapeutics (NYSE MKT: CXM), a company in the same industry as Impax Laboratories Inc. (NASDAQ: IPXL) and Osiris Therapeutics Inc. (NASDAQ: OSIR), Read More |
 |
Cardium Therapeutics in the News(0) It’s been a busy several weeks for Cardium Therapeutics (NYSE MKT: CXM) as industry attention and investor buzz continues to build around regenerative medicine companies. Generx®, Cardium’s flagship gene therapy product candidate, is a DNA-based angiogenic growth factor therapeutic being developed for the potential treatment of patients with advanced coronary artery disease. In March 2012, Cardium initiated its Phase 3 registration clinical trial in Russia which is expected to enroll approximately 100 patients at up to eight leading cardiovascular centers. The San Diego Biotechnology Read More |
 |
Cardium CEO Discusses Generx, Excellagen and MedPodium with CEOCFOInterviews.com(0) In their latest interview, www.ceocfointerviews.com spent some time with Cardium Therapeutics (NYSE MKT: CXM) CEO and Chairman Christopher J. Reinhard. The article title, “With their Regenerative Medicine Product Generx® for Coronary Artery Disease in Phase 3 Registration Study for International Markets, Cardium Therapeutics Inc. is Leading the Evolution of a Revolution” can be seen on the CEO/CFO Interviews website at: Read More |
 |
IsoRay and Others Shifting the Paradigm of Traditional Standards of Care in Cancer(0) The fight against cancer is an ongoing evolution with new technologies, procedures and compounds showing potent anti-tumor activities as stand-alone treatments or working in conjunction with traditional therapies to increase survival rates. Pioneering efforts of companies like Immunocellar Therapeutics Ltd. (NYSE MKT: IMUC), Cellceutix Corporation (OTCBB: CTIX) and IsoRay Inc. (NYSE MKT: ISR) are advancing cancer research and providing additional hope for cancer sufferers. Read More |
OTCBB News
read more
Stay Informed
Dana-Farber to Host Cellceutix Trials
Diabetes Rate Growing Exponentially
According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.
